Company profile: Unlearn
1.1 - Company Overview
Company description
- Provider of AI, digital twin, and statistical methods to enable smaller, more efficient clinical trials, offering TwinRCTs (RCTs enhanced with AI-generated digital twins), Digital Twin Generators to predict individual health outcomes over time, regulatory services to navigate and meet FDA and EMA guidelines, and PROCOVA using prognostic scores from digital twins to enhance statistical power.
Products and services
- TwinRCTs: AI-enhanced randomized controlled trials integrating AI-generated digital twins to increase trial efficiency and statistical power, enabling smaller, more efficient clinical studies
- PROCOVA: Statistically rigorous methodology leveraging prognostic scores from digital twins to enhance the statistical power of clinical trials
- Digital Twin Generators: Patient-level AI models engineered from patient-level data to predict individual health outcomes over time, generating digital twins for use within trials
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Unlearn
Bio-Optronics
HQ: United States
Website
- Description: Provider of healthcare information technology software focused on workflow optimization for healthcare organizations, offering Clinical Conductor CTMS with tools for patient recruitment, budgeting, billing, reporting, and participant engagement, integrated with other platforms for enhanced data quality and compliance; CCText two-way messaging for decentralized trial communications; and CCPay real-time participant payment reimbursements with analytics and caregiver support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bio-Optronics company profile →
RxS
HQ: United States
Website
- Description: Provider of end-to-end multi-channel sample management solutions, including LinkedRx for compliant management of pharmaceutical samples across hand-carry and direct-to-practitioner channels; TeleTargetRx contact center CRM for inside sales and sample requests; SampleCentral eSampling portal for healthcare professionals; RxS Engage telesampling and support services; and ClientConnect multi-channel reporting and analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RxS company profile →
NiKang Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NiKang Therapeutics company profile →
Median Technologies
HQ: France
Website
- Description: Provider of medical imaging software and services for oncology clinical trials, cancer screening, and clinical practice, standardizing and automating the interpretation of medical images to optimize diagnosis of cancer patients and assessment of their response to therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Median Technologies company profile →
Atomwise
HQ: United States
Website
- Description: Provider of AI and deep learning–based, structure‑based drug discovery solutions, leveraging supercomputers to identify small‑molecule candidates. Offers AtomNet technology to streamline discovery and develop a pipeline of drug candidates advancing into preclinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atomwise company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Unlearn
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Unlearn
2.2 - Growth funds investing in similar companies to Unlearn
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Unlearn
4.2 - Public trading comparable groups for Unlearn
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →